Clinical trial

A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

NCT07836660

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Part A - Placebo for IBI355 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part B -Telitacicept Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention PartB -Placebo for Telitacicept Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part A - IBI355 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-15

PhasePHASE2

Conditions

Sjögren's Diseaseunresolved

Interventions

Part A - Placebo for IBI355DRUG

Part B -TelitaciceptDRUG

PartB -Placebo for TelitaciceptDRUG

Part A - IBI355DRUG

Sponsors & collaborators

Innovent Biologics (Suzhou) Co. Ltd.lead sponsor

Mapped research locations

HefeiAnhui, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07836660 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.